Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs HealthRX

CoreAge Rx
Graded #1

Higher grade

vs+5.7
HealthRX
Graded #6

Lower grade

The verdict

CoreAge Rx takes it — 91.8/100 to 86.1/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 91.8/100 (A−).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoreAge Rx +7
92
85
Dose & formulationHealthRX +2
88
90
Clinical oversightCoreAge Rx +6
93
87
Labs & monitoringCoreAge Rx +8
90
82
FulfillmentCoreAge Rx +9
95
86
Contract termsCoreAge Rx +11
96
85
CoreAge Rx · left barHealthRX · right bar

The numbers

MetricCoreAge RxHealthRX
WeighScore91.8/10086.1/100
GradeA−B
Scorecard rank#1#6
Semaglutide$99/mo$190/mo month-to-month ($99 first month, renews at $165) · $99/mo on a 12-month prepay ($1,188)
Tirzepatide$149/mo$239/mo month-to-month ($149 first month, renews at $214) · $179/mo on a 12-month prepay ($2,148)
CoverageAll 50 statesNot publicly listed
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
CoreAge Rx

Graded #1 · A−

Strengths

  • Flat all-in price with no month-two step-up
  • Semaglutide and tirzepatide on one account
  • All 50 states, LegitScript-verified

Where it loses points

  • Not the cheapest sticker price
  • Compounded only
  • Pharmacy partner not yet publicly named
HealthRX

Graded #6 · B

Strengths

  • Physician-supervised intake with licensed providers
  • Both molecules plus a rare oral GLP tablet option
  • Transparent flat monthly pricing, no insurance required

Where it loses points

  • Compounded semaglutide/tirzepatide is not FDA-approved
  • Some tiers are company-stated and the public site is thin
  • Brand Ozempic is a steep pass-through (~$1,299)
  • State count is not publicly listed

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard